Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 25, 2024 08:30 ET | Source: Windtree Therapeutics

Windtree Eliminates $15 Million Contingent Liability to Deerfield Management Company

WARRINGTON, Pa., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions...
January 17, 2024 08:00 ET | Source: Windtree Therapeutics

Windtree Therapeutics Announces License Agreement with Lee’s Pharmaceuticals to Develop and Commercialize Istaroxime, Dual Mechanism SERCA2a Activators and Rostafuroxin for Greater China / Asia Pacific Region

Windtree to receive potential future milestones up to $138MM plus up to low double digit royalties and full coverage for all development, manufacturing, regulatory and commercialization costs for...
January 02, 2024 16:05 ET | Source: Windtree Therapeutics

Windtree Therapeutics Announces Reduction In Arrythmias In A New Study With Istaroxime And A Pure SERCA2a Activator

The new preclinical data further supports istaroxime clinical data from three Phase 2 studies Arrythmias can be a serious complication of current rescue therapies for treatment of patients with acute...
December 18, 2023 08:00 ET | Source: Windtree Therapeutics

Windtree Therapeutics Announces the Start of Patient Dosing In Phase 2 SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock

SEISMiC Extension Study results are anticipated in mid-2024 and expected to provide dose optimization for Phase 3 The Company is also progressing a parallel SCAI Stage C Phase 2 study with istaroxime...
November 16, 2023 08:00 ET | Source: Windtree Therapeutics

Windtree Therapeutics Announces Issuance of New Pure SERCA2a Activator Patent

WARRINGTON, Pa., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions...
November 09, 2023 16:15 ET | Source: Windtree Therapeutics

Windtree Therapeutics Reports Third Quarter 2023 Financial Results and Provides Key Business Updates

WARRINGTON, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions...
November 08, 2023 08:00 ET | Source: Windtree Therapeutics

Windtree to Present at the Sidoti Micro Cap Conference on November 16th

WARRINGTON, Pa., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions...
October 12, 2023 07:30 ET | Source: Windtree Therapeutics

Windtree to Present at the ThinkEquity Conference on October 19th in New York City

WARRINGTON, Pa., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions...
October 10, 2023 07:30 ET | Source: Windtree Therapeutics

Windtree to Participate in the Lytham Partners Fall 2023 Investor Conference on October 17th

WARRINGTON, Pa., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions...
October 03, 2023 08:00 ET | Source: Windtree Therapeutics

Windtree to Present at the Dawson James Small Cap Growth Conference on October 12th

WARRINGTON, Pa., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions...